drugset / Trial / NCT06512428
A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma
RandomizedSequentialOpen-labelTreatment
Summary
To evaluate the safety and efficacy of simmitinib plus irinotecan liposome in the treatment of advanced esophageal squamous cell carcinoma, and to evaluate the PK of the drug and the correlation between biomarkers and clinical efficacy of simmitinib plus irinotecan liposome.
Timeline
- Start
- 2024-03-15
- Primary completion
- 2026-01-30
- Completion
- 2026-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 70 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 180 mg/m2 | — |
| Subject | Simmitinib | Small molecule | 4 mg | — |
| Subject | Simmitinib | Small molecule | 6 mg | — |